Berenberg has revised its price target and earnings estimates for Galderma following the company's record first-half 2026 results, citing strength in the integrated model that combines injectables, skincare, and devices. The analyst's upgrade reflects confidence in Galderma's ability to cross-sell across product categories and geographies.
Business & M&A
Berenberg Backs Galderma's Integrated Model After H1 Beat
Analyst revises price target and estimates following strong first-half results.
Berenberg revises estimates upward, citing strength in Galderma's integrated injectables, skincare, and device model.
The integrated model—anchored by Botox and Juvéderm, bolstered by Alastin skincare, and supported by device partnerships—allows Galderma to capture multiple revenue streams from a single practice relationship. This structural advantage matters for practice owners evaluating supplier consolidation: a single Galderma rep can now address toxin, filler, skincare, and device needs, reducing the number of vendor relationships required. Berenberg's upgrade signals institutional confidence that this bundling strategy will sustain margin expansion and market share gains.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.